DaVita (DVA) vs Mangoceuticals (MGRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
DaVita is the larger company by market cap ($10.13 billion vs $2.7 million), about 3687.3 times the size. DaVita converts more of its revenue into profit, with a net margin of 5.5% versus -4526.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DVA | MGRX |
|---|---|---|
| Share price | $161.03 | $0.1236 |
| Market cap | $10.13B | $2.75M |
| 1-day change | +3.00% | -7.55% |
| YTD return | +41.74% | — |
| 1-year return | +33.91% | — |
| 5-year return | +65.52% | — |
| P/E ratio (TTM) | 12.19 | — |
| Forward P/E | 9.52 | — |
| EPS (TTM) | $13.21 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.64B | $456.02K |
| Revenue growth (YoY) | +6.46% | -25.96% |
| Net income (latest FY) | $746.80M | $-20.64M |
| Gross margin | — | 54.91% |
| Operating margin | 14.98% | -3954.28% |
| Net margin | 5.47% | -4526.76% |
| 52-week high | $247.49 | $1.38 |
| 52-week low | $101.00 | $0.121 |
| Distance from 52-week high | -34.93% | -91.04% |
| Analyst consensus | buy | — |
| Avg. price target upside | +38.04% | — |
| Average volume | 738.70K | 638.90K |
| Shares outstanding | 62.90M | 22.22M |
| Employees | 78,000 | 3 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DaVita is about 3687.3 times larger than Mangoceuticals by market value ($10.13B vs $2.75M).
- DaVita is more profitable, keeping 5.5 cents of every revenue dollar as net income versus -4526.8 cents for Mangoceuticals.
- DaVita grew revenue faster in its latest fiscal year (+6.46% vs -25.96%).
About DaVita
DVA stock →DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Health Care · Misc Health and Biotechnology Services · 78,000 employees
About Mangoceuticals
MGRX stock →Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States.
Health Care · Misc Health and Biotechnology Services · 3 employees
DVA vs MGRX FAQ
Which is bigger, DaVita or Mangoceuticals?
DaVita (DVA) is larger, with a market capitalization of $10.13B compared with $2.75M for Mangoceuticals (MGRX).
Are DaVita and Mangoceuticals in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.